公司
SPH Biotherapeutics (HK) Limited is a clinical‑stage biotech company dedicated to the discovery, development, and manufacturing of cell therapy products, including CAR‑T and TCR‑T, for the treatment of tumours and autoimmune diseases. The company places early research and development in Hong Kong and conducts clinical translation and commercialisation in Shanghai, operating through a model of “R&D in Hong Kong, translation in Shanghai.”
Furthermore, SPH Biotherapeutics has established a unique model by placing a “factory” inside hospitals, closely connecting benchtop research with bedside clinical studies. Founded in 2018, the company has built a solid foundation to support early‑stage clinical trials and has advanced several core pipeline products under the leadership of a joint scientist‑entrepreneur team. To date, our achievements include an intellectual property portfolio of more than 20 patents and four core technological platforms focused on T‑cell engineering and enhancement, spanning both autologous and allogeneic cell platforms.
The most advanced asset, CD19CD22 dual CAR‑T (B019), is currently in Phase I clinical trials for pediatric B‑ALL, adult B‑NHL, and SLE. In addition, the company has made breakthroughs in a non‑gene‑edited allogeneic platform using iNKT cells, which has been developed into several pipeline products targeting BCMA, CD19, and GPC3. Additional candidates are progressing through preclinical development. Through internal R&D innovation and strategic external partnerships, the company is committed to advancing its pipeline to benefit patients worldwide.
The company also provides an integrated cell‑based CDMO and clinical CRO solution designed to accelerate the journey from discovery to first‑in‑human studies. Its platform combines GMP‑grade manufacturing of plasmids, viral vectors, and cell products with IND‑enabling services and early‑phase clinical trial execution.
简介
SPH Biotherapeutics (HK) Limited is a clinical‑stage biotech developing CAR‑T, TCR‑T, and allogeneic iNKT‑based cell therapies for cancer and autoimmune diseases. With R&D in Hong Kong and clinical translation in Shanghai, the company integrates hospital‑embedded manufacturing, a robust IP portfolio, and four T‑cell engineering platforms to advance a growing pipeline, including its lead CD19CD22 dual CAR‑T program now in Phase I trials. SPH Biotherapeutics also provides integrated CDMO and clinical CRO services to accelerate the path from discovery to first‑in‑human studies.
